Pacific Biosciences
PACB
88 hedge funds and large institutions have $206M invested in Pacific Biosciences in 2014 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
10% more funds holding
Funds holding: 80 → 88 (+8)
5% more capital invested
Capital invested by funds: $197M → $206M (+$8.93M)
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
12% less call options, than puts
Call options by funds: $312K | Put options by funds: $355K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$6.67M |
| 2 |
Millennium Management
New York
|
+$5.74M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.69M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$3.38M |
| 5 |
SIM
Spark Investment Management
New York
|
+$2.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$8.13M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.17M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$2.18M |
| 4 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$1.64M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.44M |
PACB Hedge Fund Activity: Q1 2014 in Review
88 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2014, worth a combined $206M — up 4.5% from $197M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PACB positions and 10 closed out — a net gain of 8 holders — while 31 added to existing stakes and 30 trimmed.
The largest buyer was Deerfield Management, adding an estimated $6.67M. The largest seller was BlackRock Institutional Trust, cutting an estimated $8.13M.
- 88 institutional investors held Pacific Biosciences (PACB) as of Q1 2014, up from 80 in Q4 2013.
- Funds reported $206M of Pacific Biosciences stock for Q1 2014, up 4.5% quarter-over-quarter.
- 18 funds opened new Pacific Biosciences positions in Q1 2014 and 10 closed out, a net change of +8 holders.
- The largest Pacific Biosciences buyer in Q1 2014 was Deerfield Management, an estimated $6.67M added.
- The largest Pacific Biosciences seller in Q1 2014 was BlackRock Institutional Trust, an estimated $8.13M sold.
Based on aggregated 13F filings for Q1 2014.